Oncology
1h
Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.
by Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E via Oncology
Related Articles
Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.

Anticancer Res. 2019 Jul;39(7):3615-3620

Authors: Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E

Abstract
Heterocyclic rings are recognized as key components of many natural, semi-synthetic and synthetic molecules with a broad spectrum of biological activities. Among these molecules, the indole and imidazo[2,1-b][1,3,4]thiadiazole systems have recently been described as useful scaffolds for the design of anticancer agents. Herein the antitumor activity of a series of 3-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indoles, designed as hybrid structures, was assessed. Seven out of 10 compounds (1a-g) were submitted to National Cancer Institute (NCI). Remarkably, compound 1g showed antiproliferative activity against the full panel of sixty human cancer lines, with half-maximal inhibitory concentration of between 1.67 and 10.3 μM. Further studies showed antiproliferative activity of 1a-g and of three additional compounds 1h, 1i and 1l, with different substituents on the indole nucleus and phenyl ring, against three pancreatic cancer cell lines. In particular, derivatives 1g and 1h inhibited both proliferation and migration of SUIT-2 cells at concentrations lower than 10 μM. In conclusion, new indole derivatives are characterized by in vitro antitumor activity, supporting future mechanistic studies.

PMID: 31262887 [PubMed - in process]

Add tags (Currently: PubMed)
 Unread  Email Website
1h
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
by Zhou Y, Simmons J, Jordan CD, Sonbol MB, Maihle N, Tang SC via Oncology
Related Articles
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.

Clin Breast Cancer. 2019 May 18;:

Authors: Zhou Y, Simmons J, Jordan CD, Sonbol MB, Maihle N, Tang SC

Abstract
BACKGROUND: Studies suggest regular aspirin use decreases breast cancer (BRCA) risk, with high doses exerting an "anti-cancer" effect. Despite reports suggesting aspirin's protective role in BRCA, no findings on aspirin dose association(s) with treatment outcomes have been reported, nor have any molecular subtype associations by which aspirin influences outcomes been elucidated. To interrogate aspirin's effect and determine which populations may benefit from its use, we retrospectively explored data from 1227 patients with BRCA. In this population, 32 used high-dose aspirin (325 mg), 121 used low-dose aspirin (81 mg), and 1074 used no aspirin before and/or after diagnosis.
PATIENTS AND METHODS: Several association tests were performed to examine the correlations of clinical variables and PIK3CA mutations from 45 patients with BRCA who used 81 mg of aspirin daily. Kaplan-Meyer survival curves and the log-rank test were utilized to compare survival outcome differences for aspirin dose, usage history, and PIK3CA mutation status. Cox proportional hazards models were used to compute the multivariate hazard ratio (HR) for death.
RESULTS: Patients who regularly used high-dose aspirin (325 mg) had better survival outcomes than those who used low-dose aspirin (81 mg) (HR, 0.094; 95% confidence interval [CI], 0.014-0.62; P = .014). Patients who used aspirin post-diagnosis only achieved significant benefits in overall survival (HR, 0.082; 95% CI, 0.023-0.3; P = 1.39E-04). Also, a subgroup of patients in the low-dose, long-term aspirin group with a PIK3CA mutation showed a small beneficial effect (HR, 0.37; 95% CI, 0.04-3.25; P = .37).
CONCLUSION: High-dose aspirin after diagnosis may confer BRCA treatment benefits. Future studies should assess the comprehensive mechanism of aspirin for the PIK3CA mutant subgroup in a large study.

PMID: 31262687 [PubMed - as supplied by publisher]

Add tags (Currently: PubMed)
 Unread  Email Website
1h
Application of Biodegradable and Biocompatible Nanocomposites in Electronics: Current Status and Future Directions.
by Liu H, Jian R, Chen H, Tian X, Sun C, Zhu J, Yang Z, Sun J, Wang C via Oncology
Related Articles
Application of Biodegradable and Biocompatible Nanocomposites in Electronics: Current Status and Future Directions.

Nanomaterials (Basel). 2019 Jun 29;9(7):

Authors: Liu H, Jian R, Chen H, Tian X, Sun C, Zhu J, Yang Z, Sun J, Wang C

Abstract
With the continuous increase in the production of electronic devices, large amounts of electronic waste (E-waste) are routinely being discarded into the environment. This causes serious environmental and ecological problems because of the non-degradable polymers, released hazardous chemicals, and toxic heavy metals. The appearance of biodegradable polymers, which can be degraded or dissolved into the surrounding environment with no pollution, is promising for effectively relieving the environmental burden. Additionally, biodegradable polymers are usually biocompatible, which enables electronics to be used in implantable biomedical applications. However, for some specific application requirements, such as flexibility, electric conductivity, dielectric property, gas and water vapor barrier, most biodegradable polymers are inadequate. Recent research has focused on the preparation of nanocomposites by incorporating nanofillers into biopolymers, so as to endow them with functional characteristics, while simultaneously maintaining effective biodegradability and biocompatibility. As such, bionanocomposites have broad application prospects in electronic devices. In this paper, emergent biodegradable and biocompatible polymers used as insulators or (semi)conductors are first reviewed, followed by biodegradable and biocompatible nanocomposites applied in electronics as substrates, (semi)conductors and dielectrics, as well as electronic packaging, which is highlighted with specific examples. To finish, future directions of the biodegradable and biocompatible nanocomposites, as well as the challenges, that must be overcome are discussed.

PMID: 31261962 [PubMed]

Add tags (Currently: PubMed)
 Unread  Email Website